Scanogen square logo ABOUT US TECHNOLOGY

NEWS

CAREERS CONTACT US
Scanogen Entrance

News

September 20, 2019
Gregory Meehan, former General Manager of the Diagnostics Division at Becton Dickinson joins Scanogen as CCO. Greg joins the company to lead the commercialization strategy of our first product.
April 1, 2019
Thomas Borgoyn, former VP of Engineering and Software at Becton Dickinson joins Scanogen as CTO. Tom has been supporting the work of Scanogen's engineering team since 2018. Now, he formally joins the company to lead the engineering team. Tom has the experience and leadership required to complete the development and evaluation of Scanogen's automated diagnostic platform.
March 29, 2019
Scanogen expands laboratories by adding adjacent 1,200 sqft. The additional laboratory space will accelerate testing of SMS technology.
January 15, 2019
Scanogen is granted a U.S. patent with broad claims that covers the use of Single Molecule Scanning technology. US 10,179,30. 
August 31, 2018
New studies show that Single Molecule Scanning can detect microorganisms in blood and sputum at concentrations as low as one organism per milliliter of sample.
April 15, 2017
Scanogen receives $600,000 in an SBIR grant Phase I from National Institute of Aging.
February 10, 2017
Scanogen receives a new grant for $3 million from the National Institute of Allergy and Infectious Diseases to develop a rapid point-of-care assay for Tuberculosis detection.
July 5, 2016
Scanogen is granted two U.S. patents for inventions that use DNA supercoiling to detect biomolecules. US 9,382,578 describes circular biosensors that compact when target molecules are present in the sample.  US 9,382,580 describes Twist-Biosensor, a single molecule approach in which DNA tethered beads are displaced when target molecules are present in the sample.
May 15, 2016
Scanogen receives two SBIR grants, $225,000 from the National Human Genome Research Institute, and $225,000 from the National Institute of Allergy and Infectious Diseases.
February 1, 2016
Scanogen moves to new facilities. The new space has newly renovated laboratories and offices, with a total area of 4,000 sq ft.  
October 1, 2015
Scanogen TB assay is described in the  TB Diagnostics Technology and Market Landscape report. “In the context of limited-resource setting TB diagnosis, Single Molecule Scanning may offer important advantages over the available amplification-based molecular platforms.”
July 1, 2015
Scanogen receives $289,322 in phase I SBIR from the National Institute of Allergy and Infectious Diseases.
May 15, 2014
Scanogen receives two new SBIR grants, $700,000 from the National Human Genome Research Institute, and $599,760 from the National Institute of Allergy and Infectious Diseases.
September 19, 2013
Scanogen receives $636,367 in R21 grant from the IMAT program of the National Cancer Institute.
January 16, 2013
Scanogen receives $153,257 in phase I SBIR grant from the National Human Genome Research Institute.
October 31, 2011
Scanogen is registered to operate in Maryland.




home link
2018 Scanogen Inc.

3102 Lord Baltimore Dr., Suite 214, Baltimore, MD, 21244 | info@scanogen.com